CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
- PMID: 16797237
- DOI: 10.1016/j.clim.2006.05.006
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells
Abstract
We previously reported that 4C8 monoclonal antibody (mAb) provides a costimulatory signal to human CD4+ T cells and consequently induces regulatory T (Treg) cells, which are hypo-responsive and suppress the polyclonal response of bystander CD4+ cells in a contact-dependent manner. In this study, we identified the antigen of 4C8 mAb as CD52. Costimulation with Campath-1H, a humanized anti-CD52 mAb, also induced Treg cells. Anti-CD52-induced Treg cells suppressed the proliferation of both CD4+ and CD8+ T cells provided with polyclonal or allogeneic stimulation. When Treg cells were induced from Staphylococcal enterotoxin B (SEB) treated cells, they suppressed the response to SEB more efficiently than that to another superantigen, SEA. Furthermore, anti-CD52-induced Treg cells could be expanded by culture with IL-2 followed by CD52-costimulation, and co-injection of expanded Treg cells suppressed lethal xenogeneic graft versus host disease (GvHD) reactions in SCID mice caused by human peripheral blood mononuclear cells (PBMCs).
Similar articles
-
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.Cancer Res. 2003 Oct 1;63(19):6453-7. Cancer Res. 2003. PMID: 14559836
-
CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.Transpl Int. 2006 Sep;19(9):749-58. doi: 10.1111/j.1432-2277.2006.00350.x. Transpl Int. 2006. PMID: 16918536
-
Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.Int Immunol. 1995 Jan;7(1):69-77. doi: 10.1093/intimm/7.1.69. Int Immunol. 1995. PMID: 7718516
-
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies.Adv Immunol. 2007;95:111-48. doi: 10.1016/S0065-2776(07)95004-X. Adv Immunol. 2007. PMID: 17869612 Review.
-
Campath-1H treatment of multiple sclerosis.Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.
Cited by
-
Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.Hum Immunol. 2012 Feb;73(2):141-9. doi: 10.1016/j.humimm.2011.11.008. Epub 2011 Nov 23. Hum Immunol. 2012. PMID: 22154724 Free PMC article.
-
Impact of Immune-Modulatory Drugs on Regulatory T Cell.Transplantation. 2016 Nov;100(11):2288-2300. doi: 10.1097/TP.0000000000001379. Transplantation. 2016. PMID: 27490409 Free PMC article. Review.
-
Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.Transplantation. 2008 Dec 27;86(12):1695-701. doi: 10.1097/TP.0b013e31819025e5. Transplantation. 2008. PMID: 19104407 Free PMC article.
-
Alemtuzumab for the treatment of multiple sclerosis.Ther Clin Risk Manag. 2015 Mar 31;11:525-34. doi: 10.2147/TCRM.S80112. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 25848299 Free PMC article. Review. No abstract available.
-
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.Immunology. 2014 Jan;141(1):123-31. doi: 10.1111/imm.12178. Immunology. 2014. PMID: 24116901 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials